RxDoctor Payments Data

Gerald Lee, MD

Internal Medicine · Chehalis, WANPI 1730265596

Payments from drug & device makers

$991in general payments, 2019–2025

Across 47 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$355
  • Novo Nordisk$105
  • Bayer$89
  • Otsuka America Pharmaceutical, Inc.$80
  • GSK$74
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$44
  • plus $243 from 11 others

What the payments were for

  • Food & beverage$991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$991 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$3,137
Medicare patients
34
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$83,165
JardianceEmpagliflozin45$58,192
OzempicSemaglutide40$53,265
TriumeqAbacavir/Dolutegravir/Lamivudi11$47,716
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$27,423
FarxigaDapagliflozin Propanediol25$22,146
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$19,505
JanuviaSitagliptin Phosphate11$15,624
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$6,603
Novolog FlexpenInsulin Aspart17$6,458
Gabapentin211$5,820
Albuterol Sulfate HfaAlbuterol Sulfate80$4,160
Atorvastatin Calcium351$4,082
Oxybutynin Chloride ErOxybutynin Chloride116$3,483
Levothyroxine Sodium282$3,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$83,16581 claims
Boehringer IngelheimJardiance$21$58,19245 claims
Novo NordiskOzempic$105$53,26540 claims
AstraZenecaFarxiga, Breztri Aerosphere$355$41,65144 claims
GSKTrelegy Ellipta$74$27,42328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Chehalis

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →